 SOUTH PLAINFIELD, N.J., June 11, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy SMA treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently. 